{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:11:45Z","timestamp":1784945505102,"version":"3.55.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.clinthera.2015.05.508","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T01:12:17Z","timestamp":1438909937000},"page":"2086-2103.e10","source":"Crossref","is-referenced-by-count":65,"title":["Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis"],"prefix":"10.1016","volume":"37","author":[{"given":"Jing","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiquan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqiong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.05.508_bib1","series-title":"2000 Annual data report","year":"2000"},{"key":"10.1016\/j.clinthera.2015.05.508_bib2","series-title":"Harrison Principles of Internal Medicine","first-page":"2968","article-title":"Diabetes mellitus","author":"Powers","year":"2012"},{"key":"10.1016\/j.clinthera.2015.05.508_bib3","series-title":"The Washington Manual of Medical Therapeutics","first-page":"793","article-title":"Diabetes mellitus and related disorders","author":"McGill","year":"2010"},{"key":"10.1016\/j.clinthera.2015.05.508_bib4","series-title":"Williams Textbook of Endocrinology","first-page":"1329","article-title":"Type 2 diabetes mellitus","author":"Buse","year":"2008"},{"key":"10.1016\/j.clinthera.2015.05.508_bib5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0272-6386(99)70036-3","article-title":"Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy","volume":"34","author":"Lewis","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2015.05.508_bib6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2337\/diab.42.5.715","article-title":"Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients","volume":"42","author":"Rossing","year":"1993","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2015.05.508_bib7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0272-6386(96)90512-0","article-title":"The role of proteinuria in the progression of chronic renal failure","volume":"27","author":"Burton","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2015.05.508_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2015.05.508_bib9","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2337\/db05-1620","article-title":"Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74","volume":"55","author":"Retnakaran","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2015.05.508_bib10","first-page":"1111","article-title":"A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome","volume":"138","author":"Eddy","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clinthera.2015.05.508_bib11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1523-1755.2001.059002702.x","article-title":"Progression of diabetic nephropathy","volume":"59","author":"Hovind","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2015.05.508_bib12","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00125-008-1051-7","article-title":"The kidney in diabetes: Dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007","volume":"51","author":"Fioretto","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2015.05.508_bib13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/bmj.39478.378241.BE","article-title":"Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: Prospective observational study","volume":"336","author":"Amin","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2015.05.508_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.05.508_bib15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1523-1755.2000.00880.x","article-title":"Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy","volume":"57","author":"Andersen","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2015.05.508_bib16","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetesand nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.05.508_bib17","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.05.508_bib18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.05.508_bib19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s001250050140","article-title":"Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment","volume":"37","author":"Rossing","year":"1994","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2015.05.508_bib20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/bmj.299.6693.230","article-title":"Prognosis in diabetic nephropathy","volume":"299","author":"Parving","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2015.05.508_bib21","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1681\/ASN.2004090763","article-title":"Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial","volume":"16","author":"Berl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2015.05.508_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2215\/CJN.01381005","article-title":"Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: The RENAAL study","volume":"1","author":"Keane","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2015.05.508_bib23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/jdi.12029","article-title":"Comparison of spironolactone and trichlormethiazide as add-on therapy to renin\u2013angiotensin blockade for reduction of albuminuria in diabetic patients","volume":"4","author":"Hase","year":"2013","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.clinthera.2015.05.508_bib24","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.05.508_bib25","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2015.05.508_bib26","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2015.05.508_bib27","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2215\/CJN.01410210","article-title":"Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome","volume":"5","author":"Schrier","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2015.05.508_bib28","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2015.05.508_bib29","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2015.05.508_bib30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE Inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.05.508_bib31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2015.05.508_bib32","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2015.05.508_bib33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial","volume":"52","author":"Tylicki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2015.05.508_bib34","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo controlled crossover study","volume":"59","author":"Nielsen","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2015.05.508_bib35","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/ndt\/gft281","article-title":"Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial","volume":"28","author":"Esteghamati","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2015.05.508_bib36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","article-title":"Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy: A systematic review","volume":"25","author":"Mavrakanas","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clinthera.2015.05.508_bib37","article-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], Section 7.7.3.5 Medians and Interquartile ranges","author":"Higgins","year":"2011","journal-title":"The Cochrane Collaboration"},{"key":"10.1016\/j.clinthera.2015.05.508_bib38","article-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], Section 7.7.3.2 Obtaining standard deviations from standard errors and confidence intervals for group means","author":"Higgins","year":"2011","journal-title":"The Cochrane Collaboration"},{"key":"10.1016\/j.clinthera.2015.05.508_bib39","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analysis","author":"Wells","year":"2004"},{"key":"10.1016\/j.clinthera.2015.05.508_bib40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clinthera.2015.05.508_bib41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1258\/1355819021927674","article-title":"Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice","volume":"7","author":"Higgins","year":"2002","journal-title":"J Health Serv Res Policy"},{"key":"10.1016\/j.clinthera.2015.05.508_bib42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2015.05.508_bib43","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.05.508_bib44","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1440-1681.2006.04390.x","article-title":"Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor","volume":"33","author":"Ogawa","year":"2006","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.clinthera.2015.05.508_bib45","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2015.05.508_bib46","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2015.05.508_bib47","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2310\/JIM.0b013e31816d78e9","article-title":"Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial","volume":"56","author":"Saklayen","year":"2008","journal-title":"J Investig Med"},{"key":"10.1016\/j.clinthera.2015.05.508_bib48","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2015.05.508_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13410-012-0063-5","article-title":"Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension","volume":"32","author":"Kota","year":"2012","journal-title":"Int J Diabetes Dev Ctries"},{"key":"10.1016\/j.clinthera.2015.05.508_bib50","article-title":"Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy","author":"Momeni","year":"2013","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.clinthera.2015.05.508_bib51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1470320312460290","article-title":"Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease","volume":"14","author":"Nielsen","year":"2013","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.clinthera.2015.05.508_bib52","first-page":"648","article-title":"Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: A pilot randomized clinical trial","volume":"4","author":"Ziaee","year":"2013","journal-title":"Caspian J Intern Med"},{"key":"10.1016\/j.clinthera.2015.05.508_bib53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2215\/CJN.07460713","article-title":"Potassium handling with dual Renin-Angiotensin system inhibition in diabetic nephropathy","volume":"9","author":"Van Buren","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2015.05.508_bib54","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1681\/ASN.2010091001","article-title":"Changes in albuminuria predict mortality and morbidity in patients with vascular disease","volume":"22","author":"Schmieder","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2015.05.508_bib55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bmj.319.7201.24","article-title":"Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria","volume":"319","author":"Mathiesen","year":"1999","journal-title":"Br Med J"},{"key":"10.1016\/j.clinthera.2015.05.508_bib56","first-page":"324","article-title":"The initial GFR decline on antihypertensive treatment in long-term intervention studies is reversible after withdrawal of treatment","volume":"5","author":"Apperloo","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2015.05.508_bib57","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2015.05.508_bib58","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trials","volume":"167","author":"Phillips","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2015.05.508_bib59","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.05.508_bib60","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.05.508_bib61","article-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], Section 16.4.5-4.6 Methods for incorporating cross-over trials into a meta-analysis; Approximate analyses of cross-over trials for a meta-analysis","author":"Higgins","year":"2011","journal-title":"The Cochrane Collaboration"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815008474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815008474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T06:59:42Z","timestamp":1537426782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815008474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0149291815008474"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.508","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725705861.793509268","asserted-by":"object"}]},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}